ZTS vs RMD — Key Metrics

Metric ZTS (ZOETIS INC) RMD (RESMED INC)
Price85.57242.61
Market Cap34.77 Billion34.12 Billion
P/E (TTM)14.5322.04
P/B (Quarterly)10.1015.438
P/S (TTM)3.665.95
Net Profit Margin (TTM)26.127.8
Gross Margin (TTM)71.461.1
ROE (TTM)76.425.1
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

ZOETIS INC
vs
 
RESMED INC
 
ZOETIS INC
vs
 
RESMED INC
Performance Comparison
AI Model Recommendation
ZTS · ZOETIS INC

Greatly Outperform

68
UnderperformOutperform
RMD · RESMED INC

Outperform

46
UnderperformOutperform
Recommendation Summary

Stock ZTS is projected to greatly outperform the market, stock RMD is projected to outperform the market. Upfront Recommendation: ZTS.

Financial Metrics
Prices delayed ~15 min
ZTS Metrics RMD
$85.57 Price $242.61
— Market Capitalization —
14.53 Price to Earnings Ratio 22.04
3.66 Price to Sales 5.95
15.2 Price to FCF Ratio 21.21
5.13 Price to Gross Profit 9.75
47.89 Price to R&D 86.65
5.52 Price to Current Assets 9.73

ZTS vs RMD at a glance

Zoetis INC (ZTS) and Resmed INC (RMD) are both in the Healthcare sector. They are similar in size: $34.8 billion and $34.1 billion in market value.

On trailing-twelve-month figures, ZTS trades at 14.5 times trailing earnings and RMD at 22.0; net profit margins are 26.1% and 27.8%.

The Upfront Investment model currently rates ZTS Greatly Outperform and RMD Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.